ACCREDITATION
Developments in Ureteroscopic Stone Treatment
2024 Annual Meeting
October 3 – 5, 2024
Miami, FL
Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Developments in Ureteroscopic Stone Treatment (DUST). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco Joint Accreditation #4008163.
Professions in scope for this activity are listed below.
Physicians
Amedco LLC designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Objectives – After Attending This Program You Should Be Able To
- Demonstrate the indications and methodology of dusting technique during ureteroscopic laser lithotripsy when treating patients with kidney stone disease using both holmium and thulium lasers.
- Explain the effect of different laser settings and be able to select appropriate settings in different patients, to provide safe and effective stone surgery.
- Appraise the evidence on ureteroscopic stone treatment quality of life, patient selection, patient outcomes, and medical therapy to treat kidney stones.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
| First | Last | Commercial Interest |
| Jodi | Antonelli | NA |
| Marianne | Brehmer | NA |
| Casey | Dauw | Boston Scientific:Consultant,AURIS:Consultant,Cook:Speakers Bureau,Storz:Consultant |
| Brian | Eisner | Boston Scientific :Consultant,Olympus:Consultant,Cook:Consultant,Auris Robotics:Consultant,Calyxo Medical:Stock Shareholder,Dr. Arnie’s LLC:Stock Shareholder |
| Oscar | Fugita | NA |
| Khurshid | Ghani | Blue Cross Blue Shield of Michigan :Research Grant Overall Principal Investigator,Boston Scientific:Research Grant Site Principal Investigator,Boston Scientific :Consultant,Ambu:Consultant,Karl Storz:Consultant,Coloplast:Consultant,Olympus:Consultant,Urogen:Scientific/Medical Advisory Board Member,Coloplast :Research Grant Site Principal Investigator,PCORI:Research Grant Overall Principal Investigator,Lumibird:Consultant |
| Mantu | Gupta | Olympus Medical:Speakers Bureau,Cook Medical:Speakers Bureau,Boston Scientific Inc:Scientific/Medical Advisory Board Member |
| Jonathan | Harper | NA |
| Wissam | Kamal | Pusen, Cook, Coloplast:Speakers Bureau |
| Michael | Lipkin | Boston Scientific:Consultant,Cook Medical:Consultant,Storz:Scientific/Medical Advisory Board Member,Novo Nordisk:Scientific/Medical Advisory Board Member,Ambu:Scientific/Medical Advisory Board Member,Alnylam:Scientific/Medical Advisory Board Member,Olympus:Consultant |
| Palle | Osther | Ferring Pharmaceutical:Consultant |
| Amelia | Pietropaolo | NA |
| William | Roberts | Boston Scientific:Research Grant Overall Principal Investigator,Richard Wolf:Research Grant Overall Principal Investigator,Boston Scientific:Scientific/Medical Advisory Board Member |
| Tracy | Sandstrom | NA |
| Kymora | Scotland | Storz America:Consultant,AdvancedMedTech:Consultant |
| Ojas | Shah | Boston Scientific:Scientific/Medical Advisory Board Member,Boston Scientific:Speakers Bureau,Coloplast:Scientific/Medical Advisory Board Member,Coloplast:Speakers Bureau,Ambu:Scientific/Medical Advisory Board Member,Karl Storz:Speakers Bureau,Avvio:Scientific/Medical Advisory Board Member,Johnson and Johnson:Scientific/Medical Advisory Board Member |
| Sri | Sivalingam | Bard :Consultant,Fortec medical :Consultant,Cook:Consultant,Storz:Consultant |
| Necole | Streeper | NA |
| Wilson | Sui | NA |
| Thomas | Tailly | AMBU:Consultant,Dornier:Consultant,Cook Medical:Consultant,Storz:Consultant,Boston Scientific:Scientific/Medical Advisory Board Member,BD:Consultant |